FDA approves Tezspire for chronic rhinosinusitis with nasal polyps

Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation

Vasa Therapeutics secures FDA IND clearance to advance VS-041 into clinical trial for HFpEF

IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels

AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps

Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent

FDA approves Corstasis’ bumetanide nasal spray to treat edema in heart, liver, and kidney disease

Strides partners with Kenox to expand nasal spray portfolio for US market

Kenox to provide formulation and development expertise in orally inhaled and nasal drug products

Asahi Kasei Life Science to construct new plant for Planova virus removal filters

The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters

Dr. Reddy’s re-appoints G V Prasad as Co-Chairman and Managing Director

Prasad has played a key role in shaping Dr. Reddy’s into a globally respected organisation

Lupin achieves GMP certification from TGA Australia for Dabhasa API facility

Milestone Pharmaceuticals announces FDA acceptance of response to Cardamyst nasal spray CRL

Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments

Lupin launches nasal spray in US

Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals